

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

21 March 2024

SEED Innovations Limited

("SEED" or the "Company")

Transaction in Own Shares & TVR

SEED Innovations Ltd, the AIM-quoted company investment company providing shareholders with exposure to early-stage health, wellness and medical cannabis companies to which, in normal circumstances, they have limited access to, announces that it has purchased the following number of its shares of 1p each on the London Stock Exchange to be held in treasury (through Shard Capital Stockbrokers Limited ("Shard") acting as the Company's broker).

| | |
|---|---------------|
| Date of Purchase | 21 March 2024 |
| Number of shares purchased (aggregated volume): | 66,000 |
| Highest price paid per share (pence): | 1.96 pence |
| Lowest price paid per share (pence): | 1.96 pence |
| Volume weighted average price paid per share (pence): | 1.96 pence |

Following the purchase of these shares, the Company's issued ordinary share capital consists of 215,219,841 ordinary shares of which a total of 12,873,946 shares are held in treasury. The remaining 202,345,895 shares represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of the UK version of Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Shard on 21 March 2024 as part of the Programme as defined by the Company in the announcement on 29 September 2023.

Aggregate information:

| Venue | Volume-weighted average price (pence per share) | Aggregated volume |
|-------|---|-------------------|
| AIMX | 1.96 | 66,000 |

Individual transactions:

| Number of shares purchased | Transaction price (pence per share) | Time of transaction | Venue |
|----------------------------|-------------------------------------|---------------------|-------|
| 66,000 | 1.96 | 08.49.00 | AIMX |

-Ends-

For further information on the Company please visit: www.seedinnovations.co or contact:

| | | |
|--------------|----------------------|---|
| Ed McDermott | SEED Innovations Ltd | E: info@seedinnovations.co |
|--------------|----------------------|---|

| | | |
|--|---|--------------------------------|
| Lance de Jersey | | |
| James Biddle Roland Cornish | Beaumont Cornish Limited, Nomad | T: (0)20 7628 3396 |
| Isabella Pierre Damon Heath | Shard Capital Partners LLP Broker | T: (0)20 7186 9927 |
| Ana Ribeiro/ Isabel de Salis /Isabelle Morris | St Brides Partners Ltd, Financial PR | E: seed@stbridespartners.co.uk |

Notes

Seed Innovations Ltd

SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSQKDBBKBDNNB